Clinical Trials
59
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (53 trials with phase data)• Click on a phase to view related trials
Viscoelastic Coagulation for Early Sepsis Detection
- Conditions
- InfectionSepsis
- First Posted Date
- 2025-07-18
- Last Posted Date
- 2025-07-23
- Lead Sponsor
- Hellenic Institute for the Study of Sepsis
- Target Recruit Count
- 150
- Registration Number
- NCT07073456
- Locations
- 🇬🇷
ED & 4th Department of Internal Medicine, "Attikon" University Hospital, National and Kapodistrian University of Athens, Medical School, Chaidari, Attiki, Greece
Emapalumab Treatment For Anticipated Clinical Benefit In Sepsis Driven By The Interferon-Gamma Endotype (The EMBRACE Trial)
- Conditions
- Sepsis
- Interventions
- Drug: PlaceboDrug: Emapalumab-Izsg
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Hellenic Institute for the Study of Sepsis
- Target Recruit Count
- 75
- Registration Number
- NCT06694701
- Locations
- 🇬🇷
1st Department of Internal Medicine, Thriasio Elefsis General Hospital, Elefsina, Attiki, Greece
🇬🇷Clinic of Intensive Care and Pulmonary Diseases, Aghioi Anargyroi Kifissia General Oncologic Hospital, Kifissia, Attiki, Greece
🇬🇷Intensive Care Unit, Herakleion University General Hospital, Heraklion, Crete, Greece
The Incidence of Pulmonary, Cardiovascular and Renal System Non-communicable Complications Associated with the Post-acute Phase of the Infection by Covid-19
- Conditions
- Pulmonary ComplicationsCardiovascular ComplicationsRenal ComplicationsCOVID-19
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Hellenic Institute for the Study of Sepsis
- Target Recruit Count
- 345
- Registration Number
- NCT06608849
- Locations
- 🇬🇷
10th Department of Pulmonary Medicine, Sotiria Athens Hospital of Chest Diseases, Athens, Greece
🇬🇷Department of Internal Medicine, General Hospital of Argolida, Argos, Greece
🇬🇷4th Department of Internal Medicine, ATTIKON University General Hospital, Athens, Greece
Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.
- Conditions
- Pneumonia, Community-AcquiredCOVID-19 PneumoniaCardiovascular Diseases
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- Hellenic Institute for the Study of Sepsis
- Target Recruit Count
- 650
- Registration Number
- NCT06601998
- Locations
- 🇬🇷
2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece
🇬🇷10th Department of Pulmonary Medicine, Sotiria Athens Hospital of Chest Diseases, Athens, Greece
🇬🇷1st Department of Internal Medicine, General Hospital of Athens G. GENNIMATAS, Athens, Greece
Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)
- Conditions
- Community-acquired Pneumonia
- Interventions
- Drug: Tablets
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Hellenic Institute for the Study of Sepsis
- Target Recruit Count
- 330
- Registration Number
- NCT06294600
- Locations
- 🇬🇷
1st Department of Internal Medicine - General Hospital of Athens "Sismanogleio-Amalia Fleming", Athens, Greece
🇬🇷1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Athens, Greece
🇬🇷1st Department of Internal Medicine, EVANGELISMOS Athens General Hospital, Athens, Greece
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
News
Sobi Launches Phase 2a Trial of Gamifant for Interferon-Gamma-Driven Sepsis
Sobi has initiated the EMBRACE Phase 2a clinical trial to evaluate Gamifant (emapalumab) for treating interferon-gamma-driven sepsis (IDS), a newly identified endotype affecting approximately 20% of sepsis patients with 40-43% mortality rate.